vs
Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
BWX Technologies, Inc. is the larger business by last-quarter revenue ($885.8M vs $493.8M, roughly 1.8× Pediatrix Medical Group, Inc.). BWX Technologies, Inc. runs the higher net margin — 10.5% vs 6.8%, a 3.7% gap on every dollar of revenue. On growth, BWX Technologies, Inc. posted the faster year-over-year revenue change (18.7% vs -1.7%). Over the past eight quarters, BWX Technologies, Inc.'s revenue compounded faster (21.1% CAGR vs -0.1%).
BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
BWXT vs MD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $885.8M | $493.8M |
| Net Profit | $93.0M | $33.7M |
| Gross Margin | — | — |
| Operating Margin | 10.4% | 9.9% |
| Net Margin | 10.5% | 6.8% |
| Revenue YoY | 18.7% | -1.7% |
| Net Profit YoY | 30.9% | 10.5% |
| EPS (diluted) | $1.02 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $885.8M | $493.8M | ||
| Q3 25 | $866.3M | $492.9M | ||
| Q2 25 | $764.0M | $468.8M | ||
| Q1 25 | $682.3M | $458.4M | ||
| Q4 24 | $746.3M | $502.4M | ||
| Q3 24 | $672.0M | $511.2M | ||
| Q2 24 | $681.5M | $504.3M | ||
| Q1 24 | $604.0M | $495.1M |
| Q4 25 | $93.0M | $33.7M | ||
| Q3 25 | $82.1M | $71.7M | ||
| Q2 25 | $78.4M | $39.3M | ||
| Q1 25 | $75.5M | $20.7M | ||
| Q4 24 | $71.0M | $30.5M | ||
| Q3 24 | $69.5M | $19.4M | ||
| Q2 24 | $73.0M | $-153.0M | ||
| Q1 24 | $68.5M | $4.0M |
| Q4 25 | — | — | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | 25.1% | — | ||
| Q1 25 | 24.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 24.7% | — | ||
| Q1 24 | 24.6% | — |
| Q4 25 | 10.4% | 9.9% | ||
| Q3 25 | 13.1% | 13.8% | ||
| Q2 25 | 13.4% | 12.8% | ||
| Q1 25 | 14.2% | 7.0% | ||
| Q4 24 | 12.4% | 7.8% | ||
| Q3 24 | 14.4% | 6.6% | ||
| Q2 24 | 14.5% | -31.3% | ||
| Q1 24 | 15.4% | 3.2% |
| Q4 25 | 10.5% | 6.8% | ||
| Q3 25 | 9.5% | 14.5% | ||
| Q2 25 | 10.3% | 8.4% | ||
| Q1 25 | 11.1% | 4.5% | ||
| Q4 24 | 9.5% | 6.1% | ||
| Q3 24 | 10.3% | 3.8% | ||
| Q2 24 | 10.7% | -30.3% | ||
| Q1 24 | 11.3% | 0.8% |
| Q4 25 | $1.02 | $0.40 | ||
| Q3 25 | $0.89 | $0.84 | ||
| Q2 25 | $0.85 | $0.46 | ||
| Q1 25 | $0.82 | $0.24 | ||
| Q4 24 | $0.77 | $0.37 | ||
| Q3 24 | $0.76 | $0.23 | ||
| Q2 24 | $0.79 | $-1.84 | ||
| Q1 24 | $0.75 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $499.8M | $375.2M |
| Total DebtLower is stronger | — | $570.5M |
| Stockholders' EquityBook value | $1.2B | $865.9M |
| Total Assets | $4.3B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $499.8M | $375.2M | ||
| Q3 25 | $79.6M | $340.1M | ||
| Q2 25 | $37.0M | $224.7M | ||
| Q1 25 | $55.4M | $99.0M | ||
| Q4 24 | $74.1M | $229.9M | ||
| Q3 24 | $35.5M | $103.8M | ||
| Q2 24 | $48.3M | $19.4M | ||
| Q1 24 | $45.9M | $8.0M |
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $865.9M | ||
| Q3 25 | $1.2B | $890.7M | ||
| Q2 25 | $1.2B | $833.8M | ||
| Q1 25 | $1.1B | $789.2M | ||
| Q4 24 | $1.1B | $764.9M | ||
| Q3 24 | $1.1B | $732.5M | ||
| Q2 24 | $998.5M | $706.5M | ||
| Q1 24 | $946.2M | $856.2M |
| Q4 25 | $4.3B | $2.2B | ||
| Q3 25 | $3.8B | $2.2B | ||
| Q2 25 | $3.7B | $2.1B | ||
| Q1 25 | $3.1B | $2.0B | ||
| Q4 24 | $2.9B | $2.2B | ||
| Q3 24 | $2.9B | $2.1B | ||
| Q2 24 | $2.8B | $2.0B | ||
| Q1 24 | $2.8B | $2.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $127.0M | $114.1M |
| Free Cash FlowOCF − Capex | $56.8M | — |
| FCF MarginFCF / Revenue | 6.4% | — |
| Capex IntensityCapex / Revenue | 7.9% | — |
| Cash ConversionOCF / Net Profit | 1.37× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $295.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $127.0M | $114.1M | ||
| Q3 25 | $143.2M | $137.3M | ||
| Q2 25 | $159.0M | $137.2M | ||
| Q1 25 | $50.6M | $-117.5M | ||
| Q4 24 | $276.9M | $133.0M | ||
| Q3 24 | $32.6M | $91.8M | ||
| Q2 24 | $65.9M | $107.0M | ||
| Q1 24 | $33.0M | $-125.2M |
| Q4 25 | $56.8M | — | ||
| Q3 25 | $94.9M | — | ||
| Q2 25 | $126.3M | — | ||
| Q1 25 | $17.3M | — | ||
| Q4 24 | $224.4M | — | ||
| Q3 24 | $-7.7M | — | ||
| Q2 24 | $35.5M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | 6.4% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 30.1% | — | ||
| Q3 24 | -1.1% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | 7.9% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.9% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 4.5% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | 1.37× | 3.39× | ||
| Q3 25 | 1.74× | 1.91× | ||
| Q2 25 | 2.03× | 3.49× | ||
| Q1 25 | 0.67× | -5.66× | ||
| Q4 24 | 3.90× | 4.36× | ||
| Q3 24 | 0.47× | 4.72× | ||
| Q2 24 | 0.90× | — | ||
| Q1 24 | 0.48× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
